(Q77144476)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9716287%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

review article

1 reference

title

Meropenem in elderly and renally impaired patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9716287%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

B A Cunha

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9716287%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9716287%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Antimicrobial Agents

3 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9716287%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9716287%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9716287%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

107-117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9716287%20AND%20SRC:MED&resulttype=core&format=json

Population aging and health

3 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Optimal treatment of urinary tract infections in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Treatment of infections in elderly patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Urinary tract infection in men--state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Meropenem: a microbiological overview

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

A Multicenter Comparative Study of Meropenem and Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections in Hospitalized Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Pharmacokinetic studies of imipenem/cilastatin in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Pharmacokinetics of imipenem and cilastatin after their simultaneous administration to the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Pharmacokinetics of ceftazidime in acutely ill hospitalised elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Pharmacokinetics of cefotaxime and desacetylcefotaxime in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

The efficacy, safety and tolerance of ceftazidime for the treatment of bacterial infections in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Evaluation of imipenem/cilastatin for treatment of infection in an elderly population

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Meropenem clinical pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Pharmacokinetics of meropenem in subjects with various degrees of renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Pharmacokinetics of meropenem in subjects with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

Imipenem/cilastatin treatment of bacterial meningitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900031-4

7 January 2021

10.1016/S0924-8579(98)00031-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9716287%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference